EBITDA margin rate (a)
fiscal 2015 to present (c)
12.0% | |||||||
11.0% | |||||||
10.0% | |||||||
9.0% | |||||||
8.0% | |||||||
7.0% | |||||||
1Q | 2Q | 3Q | 4Q | Year | |||
2015(b)(d) | 2016(b) | 2017(b) | 2018 | 2019 | |||
Fiscal Year | 1Q | 2Q | 3Q | 4Q | Year |
2019
2018
2017
2016
2015
(b)
(b)
(b) (d)
10.2% | 10.6% | 8.8% | ||
10.0% | 9.8% | 8.0% | 7.7% | 8.8% |
10.8% | 10.2% | 8.9% | 7.9% | 9.3% |
11.3% | 11.1% | 9.8% | 9.4% | 10.3% |
10.4% |
- Amounts relate to our continuing operations. EBITDA margin rate is calculated by dividing EBITDA by Total Revenue.
- Beginning with the first quarter 2018, we adopted the new accounting standards for revenue recognition, leases, and pensions. We are presenting certain prior period results on a basis consistent with the new standards and conformed to the current period presentation. We provided additional information about the impact of the new accounting standards on previously reported financial information in a Form 8-K filed on May 11, 2018.
- Additional information as previously reported is available under "summary financials" on investors.target.com.
- 2015 included the impact of a $620 million gain on sale of our former pharmacy and clinic businesses.
Last Updated: 11/20/2019
Attachments
- Original document
- Permalink
Disclaimer
Target Corporation published this content on 20 November 2019 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 20 November 2019 12:44:01 UTC